Recombinant anti-CD4 antibodies for human therapy
AssigneeBiogen Idec Inc.
InventorsNabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
Life of this patent
Estimating the term…
Abstract
Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
Claims18
A method of treating a patient having a disease, condition or disorder characterized by an increased number of CD4 positive lymphocytes comprising administering a therapeutically effective amount of a chimeric anti-CD4 antibody that comprises heavy and light chain variable regions of an Old World Monkey antibody and human antibody constant regions, wherein said chimeric antibody inhibits CD4-positive dependent T cell responses.
Dependencies are inferred from the claim text.